MAA
ELDN icon

Managed Account Advisors’s Eledon Pharmaceuticals ELDN Stock Holding History

Managed Account Advisors’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		$3K Hold
1
– – ﹤0.01% 2958
2015
Q1 		$2K Hold
1
– – ﹤0.01% 2911
2014
Q4 		$3K Hold
1
– – ﹤0.01% 2677
2014
Q3 		$3K Buy
+1
New +$2.84K ﹤0.01% 2641

Other funds holding ELDN

NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TCP
Tourbillon Capital Partners New York $6.26M AUM 42.29% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Managed Account Advisors's ELDN Position: Q2 2015 in Review

Managed Account Advisors held its Eledon Pharmaceuticals (ELDN) position steady in Q2 2015 at 1 share worth $3K. The position accounts for ﹤0.01% of the portfolio, ranked #2958.

Managed Account Advisors first reported a position in ELDN in Q3 2014 and has held it in 4 quarters since. 50 funds tracked by Wall St. Rank hold ELDN as of Q2 2015.

  • Managed Account Advisors held 1 share of Eledon Pharmaceuticals worth $3K as of Q2 2015.
  • Managed Account Advisors left its Eledon Pharmaceuticals share count unchanged in Q2 2015.
  • Eledon Pharmaceuticals made up ﹤0.01% of Managed Account Advisors's portfolio in Q2 2015, its #2958 holding.
  • Managed Account Advisors first reported a position in Eledon Pharmaceuticals in Q3 2014 and has held it in 4 quarters since.
  • 50 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q2 2015.

Based on Managed Account Advisors's 13F filing for Q2 2015, filed 14 Aug 2015.